Venlafaxine versus placebo in the preventive treatment of recurrent major depression

Journal of Clinical Psychiatry

Volumn 65, Issue 3, 2004, Pages 328-336

  Montgomery, Stuart A ^a,d   Entsuah, Richard ^b   Hackett, David ^c   Kunz, Nadia R ^b   Rudolph, Richard L ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b PFIZER INC   (United States)

^c Clinical Research and Development   (France)

^d NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADULT; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OBSERVER VARIATION; RECURRENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 2342538379     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0307     Document Type: Article

References (59)

1. Hirschfeld RM, Schatzberg AF. Long-term management of depression. Am J Med 1994;97:33S-38S (Pubitemid 124003066)
2. Angst J. How recurrent and predictable is depressive illness? In: Montgomery SA, Rouillon F, eds. Long-Term Treatment of Depression. New York, NY: John Wiley & Sons; 1992:1-13
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19 (Pubitemid 24028993)
4. Lépine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29 (Pubitemid 27171192)
5. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996;57(suppl 2):24-30 (Pubitemid 26143976)
6. Task Force of the Collegium International Neuro- Psychopharmacologicum (CINP). Impact of neuropharmacology in the 1990s: strategies for the therapy of depressive illness. Eur Neuropsychopharmacol 1993;3:153-156
7. Anderson IM, Nutt DJ, Deakin JFW, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14:3-20
8. Lavori PW, Keller MB, Mueller TI, et al. Recurrence after recovery in unipolar MDD: an observational follow-up study of clinical predictors and somatic treatment as a mediating factor. Int J Methods Psychiatr Res 1994;4:211-229
9. Angst J. The course of affective disorders. Psychopathology 1986;19(suppl 2):47-52 (Pubitemid 17024951)
10. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-1006 (Pubitemid 29302790)
11. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340 (Pubitemid 27045015)
12. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349: 1436-1442 (Pubitemid 27212192)
13. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914-919 (Pubitemid 19208948)
14. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
15. Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999;60(suppl 17):41-45 (Pubitemid 29386040)
16. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996;168: 164-168 (Pubitemid 126425215)
17. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143:18-23
18. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 1993;7:19-23
19. Prien RF, Klett CJ, Caffey EMJ. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-425
20. Montgomery SA, Doogan DP, Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 1991;6(suppl 2):37-46
21. Thase ME. Long-term nature of depression. J Clin Psychiatry 1999;60(suppl 14):3-9 (Pubitemid 29343147)
22. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
23. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-1104 (Pubitemid 14017423)
24. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099
25. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195 (Pubitemid 23294926)
26. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153(suppl 3): 69-76 (Pubitemid 18231716)
27. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998;280:1665-1672 (Pubitemid 28532989)
28. Reimherr FW, Amsterdam JD, Quitkin FM, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998;155:1247-1253 (Pubitemid 28402520)
29. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497
30. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
31. Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-144
32. Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-236
33. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996;11:137-145 (Pubitemid 26195890)
34. Silverstone PH, Ravindran A, for the Venlafaxine XR360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60: 22-28
35. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181 (Pubitemid 30058219)
36. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000;15: 29-34 (Pubitemid 30058136)
37. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241 (Pubitemid 32183606)
38. Ballus C, Quiros G, de Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000;15:43-48 (Pubitemid 30058139)
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
41. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
42. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389 (Pubitemid 9136500)
43. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188 (Pubitemid 23294925)
44. Charney DS, Heninger GR, Sternberg DE, et al. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982;141:377-386 (Pubitemid 12030834)
45. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87 (Pubitemid 28305526)
46. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000;15:305-318 (Pubitemid 30812583)
47. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22 (Pubitemid 32613392)
48. Mindham RH, Howland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973;3:5-17
49. Montgomery SA, Kasper S. Depression: a long-term illness and its treatment. Int Clin Psychopharmacol 1998;13(suppl 6):S23-S26 (Pubitemid 28372348)
50. Paykel ES, DiMascio A, Klerman GL, et al. Maintenance therapy of depression. Pharmacopsychiatry 1976;9:127-136
51. Burrows GD. Long-term clinical management of depressive disorders. J Clin Psychiatry 1992;53(suppl 3):32-35
52. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13:55-62 (Pubitemid 28218515)
53. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-310 (Pubitemid 32280923)
54. Kasper S. The rationale for long-term antidepressant therapy. Int Clin Psychopharmacol 1993;8:225-235 (Pubitemid 23301115)
55. Rabe-Jablonska J, Poprawska I. Levels of serum total cholesterol and LDL-cholesterol in patients with major depression in acute period and remission. Med Sci Monit 2000;6:539-547 (Pubitemid 30432141)
56. Terao T, Iwata N, Kanazawa K, et al. Low serum cholesterol levels and depressive state in human dock visitors. Acta Psychiatr Scand 2000;101: 231-234 (Pubitemid 30108374)
57. Ellison LF, Morrison HI. Low serum cholesterol concentration and risk of suicide. Epidemiology 2001;12:168-172 (Pubitemid 32167750)
58. Partonen T, Haukka J, Virtamo J, et al. Association of low serum total cholesterol with major depression and suicide. Br J Psychiatry 1999; 175:259-262 (Pubitemid 29406596)
59. Effexor [package insert]. Collegeville, Pa: Wyeth; revised 2003